CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

(Reuters) - Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Ardena, a Belgium-based pharmaceutical contract manufacturer, will acquire Catalent’s facility in Somerset, New Jersey, ...